The Role of JAK/STAT Signalling in the Pathogenesis, Prognosis and Treatment of Solid Tumours

Overview

Journal Br J Cancer

Specialty Oncology

Date 2015 Jul 8

PMID 26151455

Citations 283

Authors

S J Thomas

J A Snowden

M P Zeidler

S J Danson

Affiliations

Soon will be listed here.

Abstract

Aberrant activation of intracellular signalling pathways confers malignant properties on cancer cells. Targeting intracellular signalling pathways has been a productive strategy for drug development, with several drugs acting on signalling pathways already in use and more continually being developed. The JAK/STAT signalling pathway provides an example of this paradigm in haematological malignancies, with the identification of JAK2 mutations in myeloproliferative neoplasms leading to the development of specific clinically effective JAK2 inhibitors, such as ruxolitinib. It is now clear that many solid tumours also show activation of JAK/STAT signalling. In this review, we focus on the role of JAK/STAT signalling in solid tumours, examining the molecular mechanisms that cause inappropriate pathway activation and their cellular consequences. We also discuss the degree to which activated JAK/STAT signalling contributes to oncogenesis. Studies showing the effect of activation of JAK/STAT signalling upon prognosis in several tumour types are summarised. Finally, we discuss the prospects for treating solid tumours using strategies targeting JAK/STAT signalling, including what can be learned from haematological malignancies and the extent to which results in solid tumours might be expected to differ.

Citing Articles

Enhancement of radio-sensitivity by inhibition of Janus kinase signaling with oclacitinib in canine tumor cell lines.

Owaki R, Hosoya K, Deguchi T, Konnai S, Maekawa N, Okagawa T Mol Ther Oncol. 2025; 33(1):200946.

PMID: 40051504 PMC: 11883359. DOI: 10.1016/j.omton.2025.200946.

Hepatocellular carcinoma: signaling pathways and therapeutic advances.

Zheng J, Wang S, Xia L, Sun Z, Chan K, Bernards R Signal Transduct Target Ther. 2025; 10(1):35.

PMID: 39915447 PMC: 11802921. DOI: 10.1038/s41392-024-02075-w.

STAT3 Expression in Organ-Preserved Laryngeal Carcinomas: Correlation with Treatment Resistance and Conventional Parameters.

Bayir E, Han U, Bayir O, Isik S, Saylam G, Yazilitas D Head Neck Pathol. 2025; 19(1):16.

PMID: 39907870 PMC: 11799471. DOI: 10.1007/s12105-024-01748-w.

Bayesian identification of differentially expressed isoforms using a novel joint model of RNA-seq data.

Shi X, Wang X, Jin L, Halakivi-Clarke L, Clarke R, Neuwald A PLoS Comput Biol. 2025; 21(1):e1012750.

PMID: 39888956 PMC: 11819608. DOI: 10.1371/journal.pcbi.1012750.

Using transcriptomic signatures to elucidate individual and mixture effects of inorganic arsenic and manganese in human placental trophoblast HTR-8/SVneo cells.

Freedman A, Hartwell H, Fry R Toxicol Sci. 2025; 203(2):216-226.

PMID: 39836092 PMC: 11775420. DOI: 10.1093/toxsci/kfae147.

References

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View

Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M . Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol. 2002; 168(2):762-5. View

Twyman-Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, Stelekati E . Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015; 520(7547):373-7. PMC: 4401634. DOI: 10.1038/nature14292. View

Pawlus M, Wang L, Hu C . STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells. Oncogene. 2013; 33(13):1670-9. PMC: 3868635. DOI: 10.1038/onc.2013.115. View

Kim D, Lee I, Kim S, Choi M, Kim H, Ahn S . A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling. Cancer Res. 2014; 74(8):2144-51. DOI: 10.1158/0008-5472.CAN-13-2187. View

Rath K, Naidu S, Lata P, Bid H, Rivera B, McCann G . HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer. Cancer Res. 2014; 74(8):2316-27. PMC: 4286190. DOI: 10.1158/0008-5472.CAN-13-2433. View

Brooks A, Dai W, OMara M, Abankwa D, Chhabra Y, Pelekanos R . Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science. 2014; 344(6185):1249783. DOI: 10.1126/science.1249783. View

Lee E, Fleischmann R, Hall S, Wilkinson B, Bradley J, Gruben D . Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014; 370(25):2377-86. DOI: 10.1056/NEJMoa1310476. View

Bendell J, Hong D, Burris 3rd H, Naing A, Jones S, Falchook G . Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol. 2014; 74(1):125-30. DOI: 10.1007/s00280-014-2480-2. View

10.

Bain B, Ahmad S . Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?. Br J Haematol. 2014; 166(6):809-17. DOI: 10.1111/bjh.12963. View

11.

Zhang X, Blaskovich M, Forinash K, Sebti S . Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours. Br J Cancer. 2014; 111(5):894-902. PMC: 4150266. DOI: 10.1038/bjc.2014.349. View

12.

Gallipoli P, Cook A, Rhodes S, Hopcroft L, Wheadon H, Whetton A . JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood. 2014; 124(9):1492-501. PMC: 4148771. DOI: 10.1182/blood-2013-12-545640. View

13.

Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A . Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene. 2002; 21(46):7001-10. DOI: 10.1038/sj.onc.1205859. View

14.

Sriuranpong V, Park J, Amornphimoltham P, Patel V, Nelkin B, Gutkind J . Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. 2003; 63(11):2948-56. View

15.

He B, You L, Uematsu K, Zang K, Xu Z, Lee A . SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A. 2003; 100(24):14133-8. PMC: 283558. DOI: 10.1073/pnas.2232790100. View

16.

Silvennoinen O, Schindler C, Schlessinger J, Levy D . Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. Science. 1993; 261(5129):1736-9. DOI: 10.1126/science.8378775. View

17.

Olayioye M, Beuvink I, Horsch K, Daly J, Hynes N . ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem. 1999; 274(24):17209-18. DOI: 10.1074/jbc.274.24.17209. View

18.

Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S . Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005; 11(12):1314-21. DOI: 10.1038/nm1325. View

19.

Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K . Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep. 2006; 15(6):1445-51. View

20.

Zorn E, Nelson E, Mohseni M, Porcheray F, Kim H, Litsa D . IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006; 108(5):1571-9. PMC: 1895505. DOI: 10.1182/blood-2006-02-004747. View